D.Western Therapeutics Institute,Inc.is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide.



Target disease Neuropathic pain after shingles
Development stage Filed NDA application in U.S.
Collaborative development company MEDRx Co., Ltd.
Overview DW-5LBT(MRX-5LBT) is a new type of lidocaine patch for the treatment of post-herpetic neuralgia that uses the ILTS® (lonic Liquid Transdermal System), an exclusive MEDRx technology incorporating the company’s ionic liquid expertise. DW-5LBT is being developed with the goal of targeting the market for Lidoderm®, a lidocaine patch.
In April 2020, we conducted collaborative development agreement with MEDRx. From now on, we will work with MEDRx to develop and commercialize the DW-5LBT(MRX-5LBT) in the United States.

Development Progress

2020 Apr. Conducted collaborative development agreement with MEDRx.
Aug. Filed NDA application in U.S.


D.Western Therapeutics Institute, Inc.
1-18-11, Nishiki, Naka-ku,
Nagoyashi, Aichi 460-0003 Japan
TEL 81+52-218-8785
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.